Successful discovery of TβRI (ALK5) kinase inhibitors using HTS, target-hopping and virtual screening

Chimica Oggi

Volumn 23, Issue 3, 2005, Pages 35-37

  Singh, Juswinder ^a   Ling, Leona E ^a   Sawyer, J Scott ^b   Lee, Wen Cherng ^a   Zhang, Faming ^b   Yingling, Jonathan M ^b  

^a BIOGEN   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 22144461015     PISSN: 0392839X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Cohen, P. Protein Kinases - the major drug targets of the twenty-first century? Nature Reviews Drug Discovery 2002, 1, 309-315.
2. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
3. Dancey, J.; Sausville, E. A. Issues and Progress with Protein Kinase Inhibitors for Cancer Treatment. Nature Reviews in Drug Discovery and Development 2003, 2, 296-312.
4. Adams, J. L.; Badger, A. M.; Kumar, S.; Lee, J. C. p38 MAP Kinase: molecular target for the inhibition of proinflammatory cytokines. Prog. Med. Chem. 2001, 38, 1-60.
5. Blobe, G. C.; Schiemann, W. P.; Lodish, H. F. Role of Transforming Growth Factor β in Human Disease. N. Engl. J. Med. 2000, 342, 1350-1358.
6. Dumont, N.; Arteaga, C. L. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 2003, 3, 531-536.
7. Laping, N. Therapeutic uses of smad protein inhibitors: selective inhibition of specific TGF-β activities. IDrugs 1999, 2, 907-914.
8. Eyers, P. A.; Craxton, M.; Morrice, N.; Cohen, P.; Goedert, M. Conversion of SB-203580-Insensitive MAP kinase family members to drug sensitive forms by a single amino acid substitution. Chem. Biol. 1998, 5, 321-328.
9. Wilson, K. P.; McCaffrey, P. G.; Hsiao, K.; Pazhanisamy, S.; Galullo, V. et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chemistry & Biology 1997, 4, 423-431.
10. Hertzberg, R. P.; Pope, A. J. High-throughput screening: new technology for the 21st century. Curr Opin Chem Bio 2000, 4, 445-451.
11. Callahan, J. F.; Burgess, J. L.; Fornwald, J. A.; Gaster, L. M.; Harling, J. D. et al. Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) Type 1 Receptor (ALK5). J. Med. Chem. 2002, 45, 999-1001.
12. Sawyer, J. S.; Anderson, B. D.; Beight, D. W.; Campbell, R. M.; Jones, M. L. et al. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β Type I receptor kinase domain. J. Med. Chem. 2003, 46, 3953-3956.
13. Sawyer, J. S.; Anderson, B. D.; Beight, D. W.; Campbell, R. M. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2- b]pyrazole inhibitors or the transforming growth factor-b Type I receptor kinase domain. Bioorganic and Medicinal Chemistry Letters 2004, 14, 3581-3584.
14. Milne, G.; Nicklaus, M.; Wang, S. S. Pharmacophores in Drug Design and Discovery. QSAR Environ. Res. 1998, 9, 23-38.
15. Lyne, P. D. Structure-based virtual screening: an overview. Drug Discovery Today 2002, 7, 1047-1054.
16. Singh, J.; Chuaqui, C. E.; Boriack-Sjodin, A.; Lee, W. C.; Pontz, T. et al. Successful shape-based virtual screening:The discovery of a potent inhibitor of the Type 1 TGFβ receptor kinase (TβRI). Bioorganic and Medicinal Chemistry Letters 2003, 13, 4355-4359.
17. Deng, Z.; Chuaqui, C. E.; Singh, J. Structural Interaction Fingerprint (SIFt): A Novel Method for Analyzing Three-Dimensional Protein-Ligand Binding Interactions. J. Med. Chem. 2004, 47, 337-344.
18. Chuaqui, C. E.; Deng, Z.; Singh, J. Interaction Profiles of Protein Kinase-lnhibitor Complexes and Their Application to Virtual Screening. J. Med. Chem. 2005, 48, 121-133.
19. Kirkpatrick, P. Virtual screening: Different routes to the same answer. Nature Reviews Drug Discovery 2003, 2, 947.